• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >The developing trend of monoclonal antibodies in the treatment of colorectal cancer.
【24h】

The developing trend of monoclonal antibodies in the treatment of colorectal cancer.

机译：单克隆抗体在大肠癌治疗中的发展趋势。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Monoclonal antibodies (mAbs) against growth factors, receptors and tumor-specific/tumor-selective antigens represent a rapidly growing class of pharmaceutical agents which are poised to make a major impact on the treatment of colorectal cancer. mAbs targeting the epidermal growth factor receptor and the vascular endothelial growth factor have already been approved for the treatment of metastatic colorectal cancer. Other antibodies to the same and other molecular targets implicated in tumor growth and metastasis are undergoing intense preclinical and clinical evaluation. In both the neoadjuvant and adjuvant clinical settings, although mAbs are typically administered in combination with established cytotoxic chemotherapy regimens given their synergistic effect, several agents have demonstrated efficacy when given as monotherapy. At the same time, combination therapies with multiple targeted biological agents are actively being investigated. Existing clinical data and recent progress in preclinical and clinical studies of mAbs are reviewed.
机译：针对生长因子，受体和肿瘤特异性/肿瘤选择性抗原的单克隆抗体（mAbs）代表了一类快速增长的药剂，有望对结直肠癌的治疗产生重大影响。靶向表皮生长因子受体和血管内皮生长因子的单克隆抗体已被批准用于治疗转移性结直肠癌。与肿瘤生长和转移有关的相同和其他分子靶标的其他抗体正在接受严格的临床前和临床评估。在新辅助和辅助临床环境中，尽管单克隆抗体通常与既定的细胞毒性化疗方案结合使用（鉴于它们的协同作用），但几种药物在单药治疗中已显示出疗效。同时，正在积极研究具有多种靶向生物制剂的联合疗法。综述了mAb的现有临床数据以及临床前和临床研究的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号